[Skip to Navigation]
Observation
From the American Head and Neck Society
September 17, 2020

Hyperprogression of a Sinonasal Squamous Cell Carcinoma Following Programmed Cell Death Protein-1 Checkpoint Blockade

Author Affiliations
  • 1Division of Otolaryngology, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut
  • 2King Saud University, Riyadh, Saudi Arabia
  • 3Yale Cancer Center, New Haven, Connecticut
  • 4Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
JAMA Otolaryngol Head Neck Surg. 2020;146(12):1176-1178. doi:10.1001/jamaoto.2020.2584

The introduction of immune checkpoint inhibition (ICI) into clinical practice has broadened treatment offerings for patients with recalcitrant tumors.1 Treatment with ICI acts to relieve inhibition of antitumor immunity exerted by tumor cells, thereby reinvigorating the antitumor immune response. Mounting evidence has supported ICI as an option for treatment of metastatic/recurrent head and neck squamous cell carcinomas (HNSCCs).2 However, a fraction of patients will experience hyperprogression of disease, characterized by a rapid acceleration of tumor burden following treatment with ICI.3,4 Although the consequences of hyperprogression can be catastrophic, the nature of this phenomenon remains unclear.

Add or change institution
×